Details for Patent: 9,757,406

Which drugs does patent 9,757,406 protect, and when does it expire?

Patent 9,757,406 protects EPCLUSA and is included in one NDA.

Protection for EPCLUSA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-two patent family members in nineteen countries.

Summary for Patent: 9,757,406

Title:	Combination formulation of two antiviral compounds
Abstract:	Disclosed are pharmaceutical compositions comprising Compound I, having the formula: ##STR00001## and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
Inventor(s):	Gorman; Eric (Foster City, CA), Mogalian; Erik (Foster City, CA), Oliyai; Reza (Foster City, CA), Stefanidis; Dimitrios (Mountain View, CA), Wiser; Lauren (San Francisco, CA), Zia; Vahid (Palo Alto, CA)
Assignee:	Gilead Pharmasset LLC (Foster City, CA)
Application Number:	15/282,128
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 9,757,406

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-002	Mar 19, 2020		RX	Yes	No					Y
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-001	Jun 28, 2016		RX	Yes	Yes					Y

International Family Members for US Patent 9,757,406

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	095133
Australia	2014311827
Australia	2017276223
Australia	2019264624